Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Engerix-B with or without co-administered Cervarix in healthy women aged 20 to 25 years
2007-007876-41Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2008
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatitis B (HBV) and human papillomavirus infection comparing Engerix-B + Cervarix co-administration with Engerix-B comparator group (2 arms). Primary endpoint: Hepatitis B immune response at Month 3. Started Feb 2008; status: completed.
02
Drugs
Hepatitis B vaccinehuman papillomavirus type 16 L1 capsid protein antigen
03
Conditions
hepatitis B (HBV)human papillomavirus infection
Beyond the preview
Go deeper on 2007-007876-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007876-41.